Clinical Trial Phases Explained

Clinical

Clinical trials are the backbone of drug development. Understanding each phase helps investors assess pipeline value and catalyst significance.

---

Clinical Development Overview

Drug development follows a structured pathway:

Discovery → Preclinical → Phase 1 → Phase 2 → Phase 3 → NDA/BLA → Approval
           (Animals)      (Safety)  (Efficacy) (Confirm)  (Review)

Development Timeline

| Phase | Duration | Patients | Cost | |-------|----------|----------|------| | Preclinical | 1-3 years | Animals | $10-50M | | Phase 1 | 6-12 months | 20-100 | $20-50M | | Phase 2 | 1-2 years | 100-500 | $50-100M | | Phase 3 | 2-4 years | 1,000-5,000+ | $100-500M | | FDA Review | 6-12 months | - | $2-3M |

---

Preclinical Studies

Before human trials begin, drugs must demonstrate safety in laboratory and animal studies.

Key Preclinical Work

• In vitro studies - Cell cultures, biochemical assays
• In vivo studies - Animal models (mice, rats, primates)
• Toxicology - Organ toxicity, carcinogenicity
• Pharmacokinetics - Absorption, distribution, metabolism, excretion (ADME)
• Pharmacodynamics - Mechanism of action, dose-response

IND Filing

An Investigational New Drug (IND) application must be submitted to FDA before human trials:

• Preclinical data summary
• Manufacturing information
• Clinical trial protocol
• Investigator qualifications

---

Phase 1 Trials

Primary Objectives

• Safety - Maximum tolerated dose (MTD)
• Pharmacokinetics - How the drug is processed
• Pharmacodynamics - How the drug works

Study Design

| Characteristic | Typical Parameters | |----------------|-------------------| | Participants | 20-100 healthy volunteers | | Duration | Several months | | Design | Open-label, dose escalation | | Endpoints | Safety, tolerability, PK/PD |

Dose Escalation

Phase 1 typically uses a 3+3 design:

1. Start with 3 patients at lowest dose
2. If no toxicity, escalate to next dose
3. If toxicity, expand cohort to 6 patients
4. Continue until MTD is reached

Oncology Exception

In oncology, Phase 1 often enrolls cancer patients (not healthy volunteers) because:

• Chemotherapy too toxic for healthy people
• Patients may benefit even at early stages
• Ethical considerations

---

Phase 2 Trials

Primary Objectives

• Efficacy - Does the drug work?
• Optimal dosing - Best dose for Phase 3
• Safety - Longer-term adverse events

Study Types

Phase 2a (Proof of Concept)

• Small study (~50-100 patients)
• Single-arm or small controlled trial
• Tests if drug shows any activity

Phase 2b (Dose-Ranging)

• Larger study (~100-300 patients)
• Multiple dose arms
• Identifies optimal dose for Phase 3

Study Design

| Characteristic | Typical Parameters | |----------------|-------------------| | Participants | 100-500 patients with disease | | Duration | 1-2 years | | Design | Randomized, controlled (often) | | Endpoints | Efficacy signals, safety |

Endpoints

| Type | Definition | Examples | |------|------------|----------| | Primary | Main efficacy measure | Response rate, symptom reduction | | Secondary | Supporting measures | Duration of response, QoL | | Exploratory | Hypothesis-generating | Biomarkers, subgroups |

---

Phase 3 Trials

Primary Objectives

• Confirm efficacy - Definitive proof drug works
• Characterize safety - Full adverse event profile
• Support approval - Data for NDA/BLA

Study Design

| Characteristic | Typical Parameters | |----------------|-------------------| | Participants | 1,000-5,000+ patients | | Duration | 2-4 years | | Design | Randomized, double-blind, controlled | | Endpoints | Clinical outcomes (OS, PFS, etc.) |

Pivotal Trial Requirements

• Randomized - Patients assigned by chance
• Controlled - Comparison to placebo or active comparator
• Blinded - Neither patient nor investigator knows assignment
• Adequate powered - Sufficient sample size for statistical significance
• Multi-center - Multiple sites for generalizability

Common Endpoints by Therapeutic Area

| Area | Primary Endpoints | |------|------------------| | Oncology | Overall Survival (OS), Progression-Free Survival (PFS) | | Cardiovascular | MACE (Major Adverse Cardiac Events) | | CNS/Psychiatry | Symptom scales (HAM-D, PANSS) | | Infectious Disease | Viral load, clinical cure | | Autoimmune | ACR response, symptom remission |

---

Success Rates by Phase

Based on BIO Industry Analysis 2024 data:

| Transition | Success Rate | |------------|-------------| | Phase 1 → Phase 2 | 65% | | Phase 2 → Phase 3 | 30% | | Phase 3 → NDA/BLA | 58% | | NDA/BLA → Approval | 85% | | Overall (Phase 1 → Approval) | ~10% |

Success by Therapeutic Area

| Area | Phase 1-Approval LOA | |------|---------------------| | Hematology | 26% | | Infectious Disease | 20% | | Ophthalmology | 17% | | Oncology | 8% | | CNS/Neurology | 6% | | Cardiovascular | 7% |

---

Reading Clinical Trial Results

Statistical Terms

| Term | Definition | |------|------------| | p-value | Probability result is due to chance (below 0.05 = significant) | | Confidence Interval | Range likely to contain true effect | | Hazard Ratio | Relative risk of event (HR below 1 = benefit) | | NNT | Number needed to treat for one benefit |

Red Flags in Trial Results

• Missed primary endpoint
• Narrow confidence intervals crossing 1.0
• Post-hoc subgroup analyses
• High dropout rates
• Changed primary endpoint mid-trial

Green Flags

• Met primary and secondary endpoints
• Consistent effect across subgroups
• Clean safety profile
• Large effect size
• Robust p-value (p below 0.001)

---

Adaptive and Novel Trial Designs

Adaptive Designs

• Seamless Phase 2/3 - Continuous enrollment
• Platform trials - Test multiple treatments
• Basket trials - One drug, multiple cancers
• Umbrella trials - One cancer, multiple drugs

Accelerated Programs

• Accelerated Approval - Based on surrogate endpoints
• Breakthrough Therapy - Intensive FDA guidance
• RMAT - Regenerative medicine designation

---

Summary

Understanding clinical trials helps investors assess:

1. Phase 1 = Safety first, 65% success rate
2. Phase 2 = Proof of concept, 30% success rate (highest risk)
3. Phase 3 = Confirmatory, 58% success rate
4. Overall LOA = ~10% from Phase 1 to approval
5. Therapeutic area significantly impacts success rates